Combination therapy with BRAF inhibitors for the treatment of cancer

PCT/EP2024/065545Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. It is a large subset of diseases characterized by the uncontrollable growth of abnormal cells. BRAF is a well-known proto-oncogene that is mutated in some human cancers. The Braf protein is a member of the Raf kinase family of growth signal transduction protein kinases that plays a role in regulating the mitogen-activated protein kinase (MAPK) signaling pathway, which is fundamental to cellular proliferation, differentiation and survival. Dysregulating this pathway by somatic mutations that directly hyperactivate this MAPK signaling pathway commonly causes cancer.The present invention relates to the field of cancer and, more particularly, to a combination comprising v-rar murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors and Omomyc and its use in medicine, more particularly in the prevention and/or treatment of cancer.